BofA lowered the firm’s price target on Teladoc (TDOC) to $8 from $9 and keeps a Neutral rating on the shares. October BetterHelp MAUs are tracking above the Q3 average, but the firm remains cautious on near-term trends given it is early in Q4 and management’s commentary that weaker consumer sentiment and macro uncertainties were consistent through Q3, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Mixed User Growth and Cautious Outlook Lead to Hold Rating
- Teladoc initiated with a Market Perform at BMO Capital
- Teladoc’s Growth and Execution Challenges: A ‘Show-Me’ Story with Potential Market Opportunities
- Teladoc’s Stock Dips Amid Analyst Caution
- Teladoc Health’s Earnings Call: Resilience Amid Challenges